♥ HF Guideline NavigatorESC 2026

6 › 6.2 › 6.2.1

6.2.1 Implantable cardioverter-defibrillators

Pages 38–40 · open in PDF

Recommendations in this section

  • Class ILevel AAn ICD is recommended in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability (secondary prevention), and who are expected to survive for >1 year with good functional status, in the absence of reversible causes, or unless the ventricular arrhythmia has occurred <48 h after an MI, to reduce the risk of sudden death and all-cause death.
  • Class ILevel B1An ICD is recommended in patients with symptomatic HFrEF (NYHA class II/III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.
  • Class IIaLevel B1An ICD should be considered in patients with symptomatic HFrEF (NYHA class II/III) of a non-ischaemic aetiology, and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.
  • Class IIaLevel CPrior to generator replacement for CIEDs, a shared decision-making process between the patient and a cardiologist experienced in CIEDs and HF should be considered to ensure that the balance between risks and benefits still favour a CIED.
  • Class IIbLevel CA wearable cardioverter-defibrillator may be considered in patients with HF who are at risk of sudden cardiac death for a limited period in order to increase survival as a bridge to decision for permanent ICD implantation or while listed for heart transplantation.
  • Class IIILevel B1ICD implantation for primary prevention is not recommended within 40 days of an MI as implantation during this period does not improve prognosis.
  • Class IIILevel CICD implantation is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or heart transplantation.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 38 · PDF

Ivabradine should be considered for patients with symptomatic HFrEF, LVEF ≤35%, in sinus rhythm, resting heart rate >70 b.p.m., on the highest tolerated ACE-I/ARNI, MRA, SGLT2-I, and beta-blockers to reduce the risk of HFH or CV death.294 Ivabradine should be considered in patients with symptomatic HFrEF, LVEF ≤35%, in sinus rhythm, who are unable to tolerate a beta-blocker, on the highest tolerated ACE-I/ARNI and MRA to reduce the risk of HFH or CV death.294 Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with symptomatic HFrEF with LVEF ≤40% on top of optimal FMT to reduce the risk of HFH and death.300 Hydralazine and isosorbide dinitrate may be considered in patients with symptomatic HFrEF with LVEF ≤40% who cannot tolerate ARNI, ACE-I, or ARB to reduce the risk of HFH and death.301 reduce the risk of HFH and CV death.295,297,298

selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.325 HFpEF ACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.39,40,42,319,332–337

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; nsMRA, non-steroidal mineralocorticoid receptor antagonist; RCT, randomized clinical trial; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; sMRA, steroidal mineralocorticoid receptor antagonist. a Class of recommendation. b Level of evidence. c The evidence for using MRAs in patients with HFrEF is based on RCTs conducted with sMRAs (spironolactone and eplerenone), whereas the evidence for patients with HFpEF originates from a meta-analysis of RCTs using both steroidal (spironolactone) and non-steroidal MRAs (finerenone). d This recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness. Dynamic dosing of loop diuretics has been widely accepted as effective and therefore no adequately powered RCTs have ever been conducted or are likely to be conducted for ethical reasons. e No large prospective RCT has been performed on the use of beta-blockers, ACE-I/ARNI/ARB exclusively in patients with LVEF 41%–49%.

6.2. Guideline-directed interventional therapies for chronic heart failure The term GDIT includes all guideline-directed interventional therapies for HF (see Section 3). In this section, we provide recommendations for ICDs and CRT. Other implantable devices, for which recommendations have not been made, will be discussed at the end of this section. Section 7 provides recommendations for interventional therapies in the setting of DHF, and Section 8 provides recommendations for interventional therapies in the setting of advanced HF. Section 9 covers comorbidityspecific interventional therapies.

6.2.1. Implantable cardioverter-defibrillators The recognition that arrhythmic sudden cardiac death (SCD) accounted for ∼30%–60% of all deaths in the early HF trials338 paved the way for the use of ICDs in patients with HFrEF. Antiarrhythmic drugs, such as amiodarone and dronedarone, are effective in reducing ventricular arrhythmias, but they do not prolong survival and may shorten it.339,340 In contrast, ICDs are effective in preventing SCD and prolonging survival in patients with HFrEF who are at high risk of SCD.340–344

6.2.1.1. Secondary prevention of sudden cardiac death Unlike antiarrhythmic drugs such as amiodarone, ICDs reduce mortality in cardiac arrest survivors and those with sustained ventricular arrhythmias, regardless of LVEF or presence of HF.345–348 Recommendations for secondary prevention ICD implantation are provided in the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the

prevention of sudden cardiac death.119 Cardiomyopathy-specific recommendations for secondary prevention ICD implantation are provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124

6.2.1.2. Primary prevention of sudden cardiac death in heart failure In the SCD-HeFT trial, compared to amiodarone, ICD reduced allcause death by 23% in patients with HFrEF.340 In MADIT-II, 1232 patients were randomized to an ICD or control, and ICD therapy reduced all-cause death by 31%.342 Although the risk of SCD has declined over time, the residual risk of SCD is still high (annual rate of 3.3 per 100 patient-years in PARADIGM-HF), warranting primary prevention ICD implantation in patients with HFrEF deemed at high risk of SCD.349 For details, see Supplementary data online, Section S3.1.1.1.340,342,349–352

6.2.1.3. Patient selection for implantable cardioverter-defibrillator therapy Selection of patients with HFrEF for ICD implantation should be based on LVEF thresholds established in RCTs and underlying aetiology, as individuals with non-ischaemic HF may derive less benefit than those with ischaemic heart disease.341,343,353,354 However, a meta-analysis of RCTs demonstrated an overall survival benefit, even in patients with non-ischaemic HF.344 The effect of ICD treatment depends on the competing risk of non-sudden death, both CV and non-CV. Thus, in patients with many comorbidities and older age, the benefit of ICD therapy may be substantially lower.355 Shared decision-making is essential when considering ICD implantation in patients with HF.

Gradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly

Vericiguat may be considered in patients with symptomatic HFrEF and LVEF <45% despite treatment with optimal FMT to

Page 39 · PDF

Both patient preferences and clinical factors should be carefully considered. Individualized patient information on the potential risks and benefits should be provided to support an informed decision. The presence and the extent of myocardial fibrosis, genotypes, and additional factors may help arrhythmic risk stratification in patients with cardiomyopathies.124,356,357

Recommendation Table 6 — Recommendations for implantable cardioverter-defibrillator implantation (see Evidence Tables 42–48) Recommendations

An ICD is recommended in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability (secondary prevention), and who are expected to survive for >1 year with good functional status, in the

Two studies have shown that primary prevention ICD implantation within 40 days of an MI does not improve outcomes.358,359 A 3-month period after uptitration of FMT before considering ICD implantation is reasonable. Delaying ICD implantation carries a risk of SCD at 2%–4% by 6 months and ∼7% by 1 year.360

absence of reversible causes, or unless the ventricular arrhythmia has occurred <48 h after

As with FMT, the commitment to GDIT is in most cases lifelong. Implantation of an ICD commits the patient to lifelong monitoring and the need for generator replacements. The lifelong risk of complications should be considered in the decision to implant. A further question is whether ICD generators should be replaced in patients who have not had appropriate ICD therapies. ICD shocks occur in more than 15% of patients after generator replacement in those who have not had an appropriate ICD shock during the lifetime of their first ICD generator.361 Even in patients with LVEF improvement after FMT and CRT, a considerable residual risk of SCD remains.362,363 As HFrEF and comorbidities progress, the benefit of ICD therapy may diminish. The need for ICD and the risk of SCD should be reconsidered over time and prior to every generator replacement, taking risk of SCD, remaining lifespan of the patient, risk of complications, competing risks of death due to comorbidities, frailty, and patient choice into account.364–367

6.2.1.6. Non-transvenous implantable cardioverter-defibrillator and wearable cardioverter-defibrillator In a subcutaneous ICD (S-ICD), the lead is extravascular and, therefore, not prone to intravascular infection. It is particularly attractive in patients with difficult venous access or those who are at risk of infection. The S-ICD is comparable to transvenous ICDs in terms of efficacy, complication rates, and inappropriate shock rates.368,369 Importantly, the S-ICD cannot treat bradyarrhythmia (other than post-shock pacing) and does not provide anti-tachycardia pacing. The extravascular ICD consists of a generator implanted in a subfascial or submuscular pocket and a substernally deployed lead.370 A notable advantage over the S-ICD is that the generator is similar in size to a transvenous ICD. Long-term data on efficacy and safety are required. A wearable defibrillator may be considered in patients deemed at especially high risk of SCD or as a bridge to decision for ICD implantation, although no mortality benefit has been shown in RCTs371,372 (see Supplementary data online, Section S3.1.1.2).

all-cause death.346 An ICD is recommended in patients with symptomatic HFrEF (NYHA class II/III) of an ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.340,342,373,374 An ICD should be considered in patients with symptomatic HFrEF (NYHA class II/III) of a non-ischaemic aetiology, and an LVEF ≤35% despite ≥3 months of optimal FMT, provided they are expected to survive longer than 1 year with good functional status, to reduce the risk of sudden death and all-cause death.340,341,344,375 Prior to generator replacement for CIEDs, a shared decision-making process between the patient and a cardiologist experienced in CIEDs and HF should be considered to ensure that the balance between risks and benefits still favour a CIED.376–380 A wearable cardioverter-defibrillator may be considered in patients with HF who are at risk of sudden cardiac death for a limited period in order to increase survival as a bridge to decision for permanent ICD implantation or while listed for heart transplantation.381–384 ICD implantation for primary prevention is not recommended within 40 days of an MI as implantation during this period does not 358,359

ICD implantation is not recommended in patients in NYHA class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or heart transplantation.374,385–387 CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association. a Class of recommendation. b Level of evidence.

6.2.1.5. Implantable cardioverter-defibrillator generator replacement

an MI, to reduce the risk of sudden death and

6.2.1.4. Timing of implantable cardioverter-defibrillator therapy

Page 40 · PDF

40 6.2.2. Cardiac resynchronization therapy

6.2.2.1. Cardiac resynchronization therapy for heart failure caused by abnormal cardiac conduction Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to conduction abnormalities (Figure 9 and Section 5.3.3). In patients with HF, where no other cause of HF other than abnormal cardiac conduction can be found, and there is a low likelihood of LVEF improvement, planning for CRT implantation may be considered early—even before full FMT uptitration.

6.2.2.2. Right ventricular pacing-induced heart failure As expected from the effects of ectopic cardiac stimulation, RV pacing leads to HFrEF in some patients.202,413 The incidence of pacemaker- or RV pacing-induced HF varies between 5.9% and 39%, depending on the definition.202,236–239 In the recent BUDAPEST-CRT Upgrade trial, upgrading to CRT-D significantly reduced death and HFH in patients with ≥20% RV pacing burden and QRS ≥150 ms (HR 0.27; P<.001). The BUDAPEST-CRT Upgrade trial is the first RCT and included only 360 patients in total. Therefore, CRT-D upgrade should be considered in such patients.202,237,238,412,414

6.2.2.3. Timing of cardiac resynchronization therapy implantation The timing of CRT in relation to hospitalizations has not been addressed by RCTs. In an observational study of 64 968

Figure 10 Indications for cardiac resynchronization therapy in heart failure. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HFrEF, heart failure with reduced ejection fraction; ICD, Implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction. In the decision on device implantation consider the following: patient preference, likely benefit of ICD/CRT at the patient’s age, frailty and comorbidities, risk of complications, venous access issues. aUptitration to the highest tolerated doses of HFrEF FMT (see Table 11). bInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and mortality, although reassessment of LVEF should be conducted prior to CRT implantation. (Class IIb).

In carefully selected patients with HFrEF, CRT improves cardiac function, QoL, and reduces hospitalizations and death. Landmark RCTs support CRT use across a range of HF severity.388–398 The first RCT to address the effects of CRT on morbidity and mortality was COMPANION388 in which CRT with pacemaker (CRT-P) and CRT with defibrillator (CRT-D) reduced the composite endpoint of all-cause death and hospitalizations for any cause by 20%. A reduction in all-cause death was shown with CRT-D, but not with CRT-P. In contrast, in the CARE-HF trial,392 which randomized participants to medical therapy with or without CRT-P, CRT-P reduced all-cause death and HFH. In the MADIT-CRT trial, in which 1820 patients in NYHA classes I and II were randomized to CRT-D or ICD, CRT-D reduced allcause death or HF events by 34%.397 In the REVERSE trial,396 which also involved patients in NYHA classes I and II with primary prevention ICD indications, CRT improved LVEF and reduced HFH. Importantly, in the 5-year follow-up of REVERSE, annualized death was low at 2.9% in patients randomized to ‘CRT-on’.399 Together, these findings have provided compelling evidence for using CRT across the spectrum of severity of HFrEF. For landmark trials of CRT, see Supplementary data online, Table S10.388,389,392,396–398,400–412 Figure 10 provides an overview of factors to consider when evaluating patients for CRT.